Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Expression ◽

First Line ◽

Her2 Positive ◽

P1-12-02: Patient-Reported Outcomes (PROs) from a Randomized Phase II Study (TDM4450g/BO21976) of Trastuzumab Emtansine (T-DM1) vs Trastuzumab Plus Docetaxel (HT) in Previously Untreated HER2−Positive Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs11-p1-12-02 ◽

2011 ◽

Cited By ~ 2

Author(s):

GV Bianchi ◽

J Kocsis ◽

L Dirix ◽

Y Torigoe ◽

D Lalla ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Patient Reported

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

First Line Treatment

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -

Annals of Oncology ◽

10.1093/annonc/mdw365.52 ◽

2016 ◽

Vol 27 ◽

pp. vi85

Author(s):

J. Bischoff ◽

J. Barinoff ◽

C. Mundhenke ◽

D. Bauerschlag ◽

S.D. Costa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdg111 ◽

2003 ◽

Vol 14 (3) ◽

pp. 433-440 ◽

Cited By ~ 13

Author(s):

R. Paridaens ◽

F. Van Aelst ◽

V. Georgoulias ◽

H. Samonnig ◽

V. Cocquyt ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Randomized Phase Ii ◽

Line Chemotherapy

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90846-4 ◽

2004 ◽

Vol 2 (3) ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M Untch ◽

S Kahlert ◽

L Petruzelka ◽

M Martin ◽

V Guillem-Porta ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy

Abstract PD3-09: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer: Results from the EORTC 75111- 10114 ETF/BCG randomized phase II study

10.1158/1538-7445.sabcs17-pd3-09 ◽

2018 ◽

Author(s):

H Wildiers ◽

K Tryfonidis ◽

L dal Lago ◽

P Vuylsteke ◽

G Curigliano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Older Patients ◽

Phase Ii Study ◽

Metastatic Breast ◽

Metronomic Chemotherapy ◽

Her2 Positive ◽

Abstract P6-17-23: Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

10.1158/1538-7445.sabcs18-p6-17-23 ◽

2019 ◽

Author(s):

SH Sim ◽

IH Park ◽

KH Jung ◽

S-B Kim ◽

J-H Ahn ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Trastuzumab Treatment ◽

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

Breast Cancer Research and Treatment ◽

10.1007/s10549-011-1558-3 ◽

2011 ◽

Vol 128 (2) ◽

pp. 437-445 ◽

Cited By ~ 5

Author(s):

R. I. Lalisang ◽

F. L. G. Erdkamp ◽

C. J. Rodenburg ◽

C. T. A. M. Knibbeler-van Rossum ◽

J. W. R. Nortier ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense

First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70894-2 ◽

2008 ◽

Vol 6 (7) ◽

pp. 220-221

Author(s):

A. Chan ◽

V. Ganju ◽

D. Becquart ◽

P.F. Conte ◽

L. Petruzelka ◽

...

Keyword(s):

Breast Cancer ◽

Combination Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Efficacy And Safety ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine

A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2011.03.019 ◽

2011 ◽

Vol 11 (4) ◽

pp. 211-220 ◽

Cited By ~ 23

Author(s):

Adam Brufsky ◽

Karen Hoelzer ◽

Thaddeus Beck ◽

Robert Whorf ◽

Mark Keaton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment